Comparative Effectiveness of Tropicamide 1% Versus Cyclopentolate 1% in Cycloplegic Refraction: A Randomized Clinical Study
Journal of Health, Wellness and Community Research · 16.05.2026 · 4 (10) · 1-11
DOI: 10.61919/qgbgev17 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health, Wellness and Community Research, online erschienen am 16.05.2026. Verfasst von Mubashra Ashraf und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Accurate cycloplegic refraction is essential in children because active accommodation can mask true refractive error and influence spectacle prescription. Tropicamide 1% and Cyclopentolate 1% are commonly used cycloplegic agents, but they differ in cycloplegic strength, duration of action, recovery profile, and tolerability.
Objective
To compare the cycloplegic effectiveness and adverse-effect profile of Tropicamide 1% versus Cyclopentolate 1% in children aged 5–15 years undergoing cycloplegic refraction.
Methods
This randomized, parallel-group clinical study included 50 children with suspected refractive error, allocated equally to receive either Tropicamide 1% or Cyclopentolate 1%. Each participant received two drops of the assigned agent in each eye, five minutes apart. Baseline visual acuity and pre-cycloplegic objective refraction were recorded, followed by post-cycloplegic refraction after adequate dilation. Spherical equivalent was calculated, and the change from pre- to post-cycloplegic refraction was compared between groups. Ocular and systemic adverse effects were also recorded.
Results
Baseline spherical equivalent values were comparable between groups. Cyclopentolate 1% produced a greater mean change in spherical equivalent than Tropicamide 1% in both eyes, with OD change of 1.164 ± 0.182 D versus 0.452 ± 0.130 D and OS change of 1.163 ± 0.182 D versus 0.452 ± 0.132 D, respectively (p < 0.001). Systemic symptoms were more frequent with Cyclopentolate 1% than Tropicamide 1% (100.0% vs 52.0%, p < 0.001).
Conclusion
Both agents were effective for cycloplegic refraction, but Cyclopentolate 1% produced stronger cycloplegia, while Tropicamide 1% showed better tolerability. Agent selection should balance refractive accuracy with safety, comfort, and clinical context.
Zitieren
APA
Ashraf, M., Nasir, K., Manzoor, F., Farooq, S., & Tahir, H. (2026). Comparative Effectiveness of Tropicamide 1% Versus Cyclopentolate 1% in Cycloplegic Refraction: A Randomized Clinical Study. Journal of Health, Wellness and Community Research, 4(10), 1-11. https://doi.org/10.61919/qgbgev17
Vancouver
Ashraf M, Nasir K, Manzoor F, Farooq S, Tahir H. Comparative Effectiveness of Tropicamide 1% Versus Cyclopentolate 1% in Cycloplegic Refraction: A Randomized Clinical Study. Journal of Health, Wellness and Community Research. 2026;4(10):1-11. doi:10.61919/qgbgev17
BibTeX
@article{Ashraf2026,
author = {Ashraf, Mubashra and Nasir, Khuram and Manzoor, Fatima and Farooq, Samavia and Tahir, Hasnain},
title = {Comparative Effectiveness of Tropicamide 1% Versus Cyclopentolate 1% in Cycloplegic Refraction: A Randomized Clinical Study},
journal = {Journal of Health, Wellness and Community Research},
year = {2026},
volume = {4},
number = {10},
pages = {1--11},
doi = {10.61919/qgbgev17}
}
EUVIMED